Suppr超能文献

被遗忘的老年人——过去 40 年原发性中枢神经系统淋巴瘤生存趋势的变化。

The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades.

机构信息

Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York.

Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio.

出版信息

Neuro Oncol. 2018 Apr 9;20(5):687-694. doi: 10.1093/neuonc/nox187.

Abstract

BACKGROUND

There has been significant improvement in treatment outcomes of primary central nervous system lymphoma (PCNSL) at specialized centers over the past several decades; however, it is unclear if these changes have translated to benefits in the general population.

METHODS

In this study, we utilized 2 national databases to examine survival trends over time for PCNSL: the Central Brain Tumor Registry of the United States (CBTRUS, 2000-2013) and 18 registries from the Surveillance, Epidemiology, and End Results program (SEER, 1973-2013).

RESULTS

The annual incidence of PCNSL in 2013 was 0.4 per 100000 population (CBTRUS/SEER). Incidence increased from 0.1 per 100000 in the 1970s to 0.4 per 100000 in the 1980s, correlating with an increase in the diagnosis of patients ≥70 years (1973: 0.2 vs 2013: 2.1 [SEER]). Incidence rates differed greatly between young and elderly patients (age 20-29 y: 0.08 vs 70-79 y: 4.32 [CBTRUS]). Even though the median overall survival of all patients doubled from 12.5 months in the 1970s to 26 months in the 2010s, this survival benefit was limited to patients <70 years. Survival in the elderly population has not changed in the last 40 years (6 mo in the 1970s vs 7 mo in the 2010s, P = 0.1).

CONCLUSION

The poor outcome seen in the particularly vulnerable elderly patient population highlights the need for clinical trials targeting the elderly in hopes of improving treatment strategies and survival.

摘要

背景

在过去几十年里,专门中心的原发性中枢神经系统淋巴瘤(PCNSL)的治疗结果得到了显著改善;然而,尚不清楚这些变化是否对普通人群有益。

方法

在这项研究中,我们利用两个国家数据库来研究 PCNSL 的时间生存趋势:美国中枢神经系统肿瘤登记处(CBTRUS,2000-2013 年)和监测、流行病学和最终结果计划(SEER,1973-2013 年)的 18 个登记处。

结果

2013 年 PCNSL 的年发病率为每 10 万人中 0.4 例(CBTRUS/SEER)。发病率从 20 世纪 70 年代的每 10 万人 0.1 例增加到 20 世纪 80 年代的每 10 万人 0.4 例,与 70 岁以上患者诊断的增加相关(1973 年:0.2 比 2013 年:2.1 [SEER])。年轻和老年患者的发病率差异很大(年龄 20-29 岁:0.08 比 70-79 岁:4.32 [CBTRUS])。尽管所有患者的中位总生存期从 20 世纪 70 年代的 12.5 个月增加到 2010 年代的 26 个月,但这种生存获益仅限于<70 岁的患者。在过去的 40 年中,老年患者的生存没有改变(20 世纪 70 年代为 6 个月,2010 年代为 7 个月,P=0.1)。

结论

在特别脆弱的老年患者群体中看到的不良预后突出表明,需要针对老年人进行临床试验,以期改善治疗策略和生存。

相似文献

2
Increasing incidence of primary central nervous system lymphoma but no improvement in survival in Sweden 2000-2013.
Eur J Haematol. 2018 Jan;100(1):61-68. doi: 10.1111/ejh.12980. Epub 2017 Oct 25.
3
Descriptive epidemiology of germ cell tumors of the central nervous system diagnosed in the United States from 2006 to 2015.
J Neurooncol. 2019 Jun;143(2):251-260. doi: 10.1007/s11060-019-03173-4. Epub 2019 Apr 25.
5
Partnership for defining the impact of 12 selected rare CNS tumors: a report from the CBTRUS and the NCI-CONNECT.
J Neurooncol. 2019 Aug;144(1):53-63. doi: 10.1007/s11060-019-03215-x. Epub 2019 Jun 17.
7
Trends in primary central nervous system lymphoma incidence and survival in the U.S.
Br J Haematol. 2016 Aug;174(3):417-24. doi: 10.1111/bjh.14073. Epub 2016 Mar 28.
10
Incidence and outcomes of primary central nervous system lymphoma in solid organ transplant recipients.
Am J Transplant. 2018 Feb;18(2):453-461. doi: 10.1111/ajt.14465. Epub 2017 Sep 2.

引用本文的文献

1
First case of primary CNS lymphoma in a patient with severe combined immunodeficiency carrying a novel ZAP70 mutation: a case report.
Ann Med Surg (Lond). 2025 Jul 15;87(9):6101-6106. doi: 10.1097/MS9.0000000000003591. eCollection 2025 Sep.
4
Outcomes at a single institution with MTR induction and consolidation in the management of primary CNS lymphoma.
Blood Neoplasia. 2025 Apr 16;2(3):100102. doi: 10.1016/j.bneo.2025.100102. eCollection 2025 Aug.
6
Novel Therapies in Primary Central Nervous System Lymphoma.
Clin Pharmacol. 2025 May 28;17:97-117. doi: 10.2147/CPAA.S501065. eCollection 2025.
9
Post-marketing surveillance of tirabrutinib in 189 patients with r/r primary central nervous system lymphoma.
Future Oncol. 2025 Jun;21(15):1837-1847. doi: 10.1080/14796694.2025.2507561. Epub 2025 May 27.
10
Role of Radiotherapy in PCNSL within the Current Therapeutic Landscape: a Comprehensive Review.
Curr Treat Options Oncol. 2025 May 8. doi: 10.1007/s11864-025-01327-3.

本文引用的文献

3
High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study).
Leukemia. 2017 Apr;31(4):846-852. doi: 10.1038/leu.2016.334. Epub 2016 Nov 15.
7
Trends in primary central nervous system lymphoma incidence and survival in the U.S.
Br J Haematol. 2016 Aug;174(3):417-24. doi: 10.1111/bjh.14073. Epub 2016 Mar 28.
9
R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma.
Blood. 2015 Feb 26;125(9):1403-10. doi: 10.1182/blood-2014-10-604561. Epub 2015 Jan 7.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验